Member Info for SGD27

OK, it's just that saying "completed" was a bit confusing. It didn't mean the IIa trial (or even the treatment of the first patient of 100) has been completed?

@Zebra04 "In this case that was completed on a single patient."

Just wondering, where did you get that from please?

Spoke too soon!

LFS - no change, just the recalculated percentage.

(@xxxyyyzzz : nice find!)

We must be due a bundle of TR1s with the new shares coming online yesterday.

But don't forget, the first patient may have been given the placebo!

@RollingInit Thanks for the link.

People need to be clear that this is referring to an injected interferon product, which is not SNG001.

Milcait is right. This is a collaboration between AZ and a Southampton University research group. It does NOT directly involve SNG, though there is an overlap of personnel, and a historical collaboration.

Some very strange reactions to this discussion. The only explanation that I can come up with is that they didn't understand the word 'efficacy'? Bye for now.

Yes, I noticed that 400 too, and wasn't sure exactly what it implied.

For reference :

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB

Hi Milcait,
Well that was really my point, their trial was also double blind yet it stopped early. (But tell me if I've misunderstood!)

I'm surprised no-one's mentioned this RNS by AZN today :

https://www.investegate.co.uk/astrazeneca-plc--azn-/rns/farxiga-ckd-trial-early-stop-for-positive-efficacy/202003300700070048I/

It's not directly relevant, and it's a Phase 3 trial (ours being Phase 2), but it's quite interesting as an example of a fast-tracked trial which has been "stopped for overwhelming efficacy". So it can happen. Like ours, it appears to be double-blinded, so I'm guessing it must have became obvious that 50% of the patients were improving dramatically.

Although I spotted it this morning I decided not to post during trading hours, as like everything else here it's sure to be misunderstood, quoted out of context, over-hyped and used as ramp-fodder.

Anyway, now that they've got this sorted out I expect AZN will be looking for something else to spend their time on, so maybe ... oops, sorry, doing it myself now.

From yesterday, don't think it's been posted here yet.

https://www.fieldfisher.com/en/sectors/life-sciences/life-sciences-law-blog/fieldfisher-advises-aim-quoted-synairgen-plc-on-it

"
Commenting on the fundraising, Ed Westhead, partner at Fieldfisher, said:

"We are delighted to have helped Synairgen on this important fundraising for the company. The funds raised will allow them to start trialling SNG0001 immediately in COVID-19 patients.

The over-subscribed fundraising shows that the capital markets are still open for business even during the lockdown and where no physical investor roadshows can take place.

We hope that there is a successful outcome to the trial, which could be a major breakthrough in the fight against the coronavirus."
"

@Warwicklad "LF Solutions is one of the funds run by Link Asset Services. It has nothing to do with LF Equity Income Fund."

Link Fund Solutions Ltd is not a fund. It is a company, and is acting as "Authorised Corporate Director" for funds including the LF Equity Income Fund.

@Warwicklad : Just trying to understand youur post; are you saying that the shares held by LFS are not part of the LF Equity Income Fund (formerly named LF Woodford Equity Income Fund) which is currently in the process of being wound up, with letters like this being sent out :

https://equityincome.linkfundsolutions.co.uk/media/bw1gsgrh/20th-march-2020-investor-notification-regarding-the-second-capital-distribution-to-investors.pdf

@SamJSung : Yes, very interesting post, thanks.

And it made me think - what if Astra (or whoever) made a bid not just for Link's shares but also Lansdowne, Licht & Griffiths. That adds up to 55.7% = control! Or do you think that is too far fetched?

Just noticed this late addition to Warwicklad's list :-O

17:06:48 27-Mar-2020 46.00 GBX 824,000 379,040.00 Off-book XOFF

Yes, all the signs are good here. But that doesn't mean we can't discuss the worst case scenario. (Has to be outside trading hours though, to avoid being labelled troll/deramper/etc.!)

@Warwicklad "the downside is dire!"

Maybe not so bad, allowing for LOXL2, the BioBank, and also (soon) the £14m cash, not all of which will be gone when the results come out.

There's also COPD, though admittedly its success/failure is likely correlated with COVID19.

@xxxyyyzzz : Good idea - but it might compromise my identity if he reads this BB! Perhaps later...

BTW for anyone interested, the holdings page has now been updated to reflect Licht's reduced holdings. Nothing else has changed AFAICS.

https://www.synairgen.com/investors/major-shareholders/

There are some biggies here :

https://www.londonstockexchange.com/exchange/prices-and-markets/stocks/exchange-insight/trade-data.html?fourWayKey=GB00B0381Z20GBGBXASX1